Positron Emission Tomography Market Rising Trends, Demand, and Future Scope 2023 to 2028 - GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands)

Positron Emission Tomography Market in terms of revenue was estimated to be worth $2.5 billion in 2023 and is poised to reach $3.5 billion by 2028, growing at a CAGR of 6.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising geriatric population, various chronic diseases, and increasing healthcare expenditure increasing public-private funds and investments in emerging markets.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46142162&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Browse in-depth TOC on "Positron Emission Tomography Market"

111 - Tables
36 - Figures
173 - Pages

PET/CT segment of the global positron emission tomography market to register significant growth rate over the forecast period of 2023-2028

Based on the product, the global market is segmented into Standalone PET syetems, PET/CT systems, and PET/MRI systems. The PET/CT segment is anticipated to register the highest growth rate over the forecast period. The PET/CT segment accounted for the highest share of the positron emission tomography market in 2022.

Oncology segment accounted for the largest share of the positron emission tomography market, by application in 2022.

Based on application, the global market is segmented into oncology, cardiology, neurology and other applications. Oncology applications accounted for the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period. Factors such as the rising incidence of cancer cases, the growing geriatric population, and the launch of integrated modalities drive the growth of PET products.

The hospital and surgical centers segment accounted for the largest share of the positron emission tomography market, by end user, in 2022

Based on end user, the global positron emission tomography market is segmented into hospitals and surgical centers, diagnostic and imaging clinics, ambulatory surgery centers, and other end users. The hospital and surgical centers segment accounts for the largest share of the market in 2022. Factors attributing to the share of this particular are increasing funds and rising healthcare expenditure for the expansion of healthcare infrastructure are driving the growth of this segment.

The Asia Pacific market to register the highest growth in the market during the forecast period

The Asia Pacific positron emission tomography market is estimated to register the highest growth from 2023 to 2028. The top and major players in the market are expanding their manufacturing facilities in the regions of APAC. This region is having a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=46142162&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Positron Emission Tomography Market Dynamics:

Drivers:

Growing adoption of multimodal PET imaging devices

Restraints:

High Capital and operational costs
Opportunities:

Increase in PET utilization for the detection of breast cancer

Challenges:

Availability of alternate imaging technologies

Key Market Players:

As of 2022, prominent players in the positron emission tomography market are GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), Canon Inc. (Japan), Shanghai United Imaging Healthcare Co., Ltd (China), and Shimadzu Corporation (Japan).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=46142162&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Recent Developments:

In May 2021, Zionexa, a top innovator in in-vivo biomarkers for oncology and neurology, has been acquired by GE Healthcare. This acquisition will enable GE Healthcare to advance Zionexa's pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18).

Cerianna can be used in conjunction with biopsy to detect estrogen receptor (ER) positive lesions, providing valuable information for treatment selection in patients with recurrent or metastatic breast cancer. The aim is to bring these biomarkers to market and promote more personalized healthcare.

In February 2023, United Imaging, a renowned global leader in advanced medical imaging and radiotherapy equipment, participated as a Platinum partner at Arab Health 2023 held in Dubai, UAE from January 30 to February 2. They showcased an extensive range of cutting-edge medical imaging devices including the HD TOF PET/MR uPMR 790, which is capable of producing high-quality images; the uCT 960+, a 16cm detector/640 slice CT scanner that is the fastest cardiac CT scanner in the world; the uMI 780, an ultra-fast high-resolution digital PET/CT scanner; the uMR 680, a 1.5T Wide Bore MRI System with "3T-like" performance, powered by uAiFI; and the uDR 380i Pro, the most compact mobile DR system.

In May 2022, Mediso Ltd has recently acquired Bartec Technologies Ltd, a UK-based company that specializes in providing and supporting Nuclear Medicine and Molecular Imaging equipment and accessories.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/positron-emission-tomography-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/positron-emission-tomography.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.